SYJONEK Trademark

Trademark Overview


On Monday, May 18, 2020, a trademark application was filed for SYJONEK with the United States Patent and Trademark Office. The USPTO has given the SYJONEK trademark a serial number of 88920651. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, December 20, 2021. This trademark is owned by Celgene Corporation. The SYJONEK trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Phar...
syjonek

General Information


Serial Number88920651
Word MarkSYJONEK
Filing DateMonday, May 18, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, December 20, 2021
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 23, 2021

Trademark Statements


Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, June 2, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCelgene Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901

Party NameCelgene Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901

Trademark Events


Event DateEvent Description
Monday, December 20, 2021ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, December 20, 2021ABANDONMENT - NO USE STATEMENT FILED
Tuesday, May 18, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, March 23, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 23, 2021PUBLISHED FOR OPPOSITION
Wednesday, March 3, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Saturday, February 13, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, February 10, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, February 9, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, February 9, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Saturday, August 15, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Saturday, August 15, 2020NON-FINAL ACTION E-MAILED
Saturday, August 15, 2020NON-FINAL ACTION WRITTEN
Saturday, August 15, 2020ASSIGNED TO EXAMINER
Tuesday, June 2, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, May 21, 2020NEW APPLICATION ENTERED IN TRAM